摘要
目的:考察磺酸基巯基壳聚糖微球(STCM)的血液相容性。方法:以相同直径的玻璃微球为对照组,分别测定微球对家兔血液的动态凝血时间、静态凝血时间,及对血小板、红细胞的黏附和激活、对红细胞的溶血性和对血栓的形成的影响。结果:STCH实验组和对照组的动态凝血时间均为50 min;STCH的静态凝血状况表现出一定的时间依赖性;只有少数微球表面物理性黏附少量的红细胞;STCH表面黏附的血小板形态圆整、光滑,没有发生形变;STCH在血液中的浓度为100和1 mg.mL-1时,其溶血率分别为3.2%和0.8%;对照组所形成的血栓平均重量约(41±3)mg,实验组的平均重量约(47±2)mg。结论:初步实验证实,磺酸基巯基壳聚糖微球具有良好的血液相容性,提示其具有潜在的医用前景。
Objective： To investigate the hemocompatibility of sulfonic-thiol-chitosan microspheres （STCM） in vitro. Methods： Glass microspheres with similar diameter were used as control, the changes in dynam- ic and static clotting time of rabbit blood were determined, respectively. The effects STCM on the adhesion and ac- tivation of platelets and erythrocytes, hemolysis and formation of thrombus were evaluated. Results： The dynamic clotting time of rabbit blood was 50 min, and the change in static clotting time was time-dependent. Only a few erythrocytes physically adhered to the surface of STCM, and the shape of platelets adhered to the surface of STCM was normally roundness and smooth. The haemolytic index was 3.2% and 0.8% at STCM concentrations of 100 and 1mg mL-1, respectively. The average weights of thrombus caused by glass microspheres and STCM were （41 ± 3） and （47 ± 2） mg, respectively. Conclusion： These results preliminarily confirm the good hemocompati- bility of STCM, which may have potential medical uses.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2013年第16期1962-1965,共4页
Chinese Journal of New Drugs
基金
福建省自然科学基金(2010J01208)
关键词
磺酸基巯基壳聚糖
微球
栓塞剂
介入治疗
sulfonic-thiol-chitosan
microspheres
embolization agents
interventional treatment
